Effects of taking neratinib/neratinib after one year

Neratinib/Neratinib is a targeted drug mainly used to treat HER2-positive breast cancer. Its mechanism of action is to block tumor growth and spread by inhibiting the activity of HER2 receptors. The effect of neratinib after one year mainly depends on the patient's individual situation and disease characteristics.

Neratinib is often used in early treatment after breast cancer surgery to reduce the risk of tumor recurrence. According to clinical trial data, neratinib combined with other drugs can prolong disease-free survival and disease-free survival. Studies have shown that the outcomes of patients with early-stage HER2+ breast cancer who received intensive adjuvant therapy with neratinib for 1 year were improved. Compared with patients who did not complete the recommended treatment duration, patients who completed treatment showed significant improvements in disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS). Neratinib, used after 1 year of standard adjuvant treatment with trastuzumab, can further reduce the risk of recurrence. Specifically, 1 year of neratinib treatment can reduce the risk of invasive breast cancer by 26%. This data is based on the results of the ExteNET phase III randomized study, which showed the therapeutic effect of neratinib in reducing the recurrence of breast cancer.

However, each patient's response and treatment outcomes may vary. During treatment, neratinib may cause some side effects, including nausea, vomiting, diarrhea, fatigue, etc. These side effects usually diminish over the course of treatment and can be alleviated with appropriate supportive care. After a year, most patients' side effects gradually disappear or lessen. If the patient can use neratinib correctly according to the doctor's guidance and complete the entire treatment process, it is possible to achieve better treatment results after one year.